BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33421110)

  • 1. Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells.
    Uchida Y; Matsushima T; Kurimoto R; Chiba T; Inutani Y; Asahara H
    FEBS Lett; 2021 Mar; 595(5):563-576. PubMed ID: 33421110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.
    Xie Y; Ding J; Cui X; Wu M; Huang C; Zhang R; Wang J; Li X; Cen S; Zhou J
    Eur J Pharm Sci; 2020 Jan; 142():105088. PubMed ID: 31626963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
    Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
    Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
    Ganesan A; Ahmed M; Okoye I; Arutyunova E; Babu D; Turnbull WL; Kundu JK; Shields J; Agopsowicz KC; Xu L; Tabana Y; Srivastava N; Zhang G; Moon TC; Belovodskiy A; Hena M; Kandadai AS; Hosseini SN; Hitt M; Walker J; Smylie M; West FG; Siraki AG; Lemieux MJ; Elahi S; Nieman JA; Tyrrell DL; Houghton M; Barakat K
    Sci Rep; 2019 Aug; 9(1):12392. PubMed ID: 31455818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
    Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
    Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells.
    Khan F; Pandey P; Mishra R; Arif M; Kumar A; Jafri A; Mazumder R
    Anticancer Agents Med Chem; 2021; 21(4):532-541. PubMed ID: 32723260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based screening of programmed death ligand 1 (PD-L1).
    Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S
    Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors.
    Cheng B; Xiao Y; Xue M; Cao H; Chen J
    J Med Chem; 2020 Dec; 63(24):15389-15398. PubMed ID: 33272018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
    Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
    J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.
    Fattakhova E; Hofer J; DiFlumeri J; Cobb M; Dando T; Romisher Z; Wellington J; Oravic M; Radnoff M; Patil SP
    ChemMedChem; 2021 Sep; 16(18):2769-2774. PubMed ID: 34117723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
    Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
    Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
    Hara T; Miyake H; Hinata N; Fujisawa M
    Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.